AstraZeneca PLC (NASDAQ:AZN)’s Q4 2024 financial results highlight robust growth despite some challenges. Total revenue for the year increased by 21%, driven by strong performances across all ...
Parnassus Growth Equity Fund stated the following regarding AstraZeneca PLC (NASDAQ:AZN) in its Q4 2024 investor letter: “We sold two Health Care positions during the quarter, pharmaceutical ...
Second, thanks to the progress of our collaboration with AstraZeneca. Up to year-end 2024, $47 million have been paid to Cellectis under the joint research and collaboration agreement of which $25 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback